As new challenges to drug safety emerge, Teva works with government officials, industry partners, patient representatives and other key stakeholders to develop smart, effective responses. We strongly support efforts to deter drug counterfeiting and strengthen inspections of domestic and foreign facilities.

• Prescription Drug Anti-Counterfeiting – Threats to the integrity of the drug supply represent a national problem that requires a national solution rather than the current patchwork of state-by-state plans. Real-world experience shows that counterfeiters typically target high-priced drugs with strong consumer demand, and deterrent efforts should start with these at-risk medications. Any anti-counterfeiting system should use proven technology, be phased in so there is no disruption of patient access to medicines and apply to all manufacturers, including contract suppliers, packagers and other third-party entities.

• Foreign Inspections – In a global marketplace, foreign facilities should be held to the same standards as domestic plants, including government inspections at least once every two years and more frequently if FDA detects problems. Teva supports: 1) taking a risk-based approach that allows FDA to focus on areas with a higher potential for concerns, 2) charging facility fees to finance inspection, including additional charges for re-inspection, and 3) establishing an on-the-ground presence in countries with a large share of registrations and cited problems